Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575482 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
A Phase 1 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02575482 is a Phase 1 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 64 participants.
The verdict
NCT02575482, a Phase 1 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-D4010 in healthy male subjects following single or multiple ascending doses.
Interventions
- DRUG Placebo
- DRUG SUVN-D4010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575482
The ClinicalTrials.gov registry entry for NCT02575482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02575482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575482 about?
NCT02575482 is a clinical study titled "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects". The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-D4010 in healthy male subjects following single or multiple ascending doses.
What is the current status of trial NCT02575482?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02575482?
The interventions under investigation include: Placebo (DRUG), SUVN-D4010 (DRUG).
Who is sponsoring clinical trial NCT02575482?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.